Artini et al. provided evidence that 12 weeks of treatment with MYO-INS were effective in reducing plasma LH (p < 0.005), prolactin (p < 0.05), LH/FSH (p < 0.01), and insulin resistance measured by HOMA-IR index (p < 0.01) [20]. This evidence concerns the gene PLOD1 and Insulin resistance.